首页> 外国专利> (e) Methods for preparing N - (4 - (3 - Chloro - 4 - (2 - piridinilmetoxi) anilino) - ethoxy - 3 - cyano - 7 - 6 quinolinil) - 4 - (dimethylamino) - 2 / - as maleate Salt, Pharmaceutical compositions for the inhibition of the kinase activity her - isolated 2 and Crystal forms of these salts maleate

(e) Methods for preparing N - (4 - (3 - Chloro - 4 - (2 - piridinilmetoxi) anilino) - ethoxy - 3 - cyano - 7 - 6 quinolinil) - 4 - (dimethylamino) - 2 / - as maleate Salt, Pharmaceutical compositions for the inhibition of the kinase activity her - isolated 2 and Crystal forms of these salts maleate

机译:(e)制备N-(4--(3--氯-4-(2--吡啶二甲氧基)苯胺基)-乙氧基-3-氰基-7-6喹啉基)-4-(二甲氨基)-2 /-作为马来酸盐的方法盐,用于抑制激酶活性的药物组合物her-分离的2和这些盐的晶型马来酸盐

摘要

Forms of maleate Salt of (e) - N - (4 - [3 - (4 - (2 - chlorine - piridinilmetoxi) anilino] - 3 - cyano - ethoxy - 6 - 7 - quinolinil} - 4 - (dimethylamino) - 2 - /, Methods for preparing forms of maleate Salt Crystal Associated Compounds, and Pharmaceutical compositions containing the salts maleate.Maleate salts are useful in the treatment of cancer, particularly those affected by Family Kinases of the epidermal growth factor receptor.Claim 1: a method for the preparation of (e) - N - (4 - [3 - (4 - (2 - chlorine - piridinilmetoxi) anilino] - 3 - cyano - ethoxy - 6 - 7 - quinolinil} - 4 - (dimethylamino) - 2 / - as maleate Salt,Characterized by understanding the mixing Stage: (e) - N - (4 - [3 - (4 - (2 - chlorine - piridinilmetoxi) anilino] - 3 - cyano - ethoxy - 6 - 7 - quinolinil} - 4 - (dimethylamino) - 2 - / and Maleic acid in a Water alcohol Solution a high temperature. Claim: a compound characterized by 14 belong to the set consisting of: group of formulas (1).A method for preparing claim 17: maleate monohydrate (e) - N - (4 - [3 - (4 - (2 - chlorine - piridinilmetoxi) aniiino] - 3 - cyano - ethoxy - 6 - 7 - quinolinil) - 4 - (dimethylamino) - 2 - / understand the selected stages characterized by the Group consisting of:.Dissolves maleate (e) - N - (4 - [3 - (4 - (2 - chlorine - piridinilmetoxi) anilino] - 3 - cyano - ethoxy - 6 - 7 - quinolinil} - 4 - (dimethylamino) - 2 - / with an anhydrous Organic Solvent, adding Water, and filtered; b.Dissolves maleate (e) - N - (4 - [3 - (4 - (2 - chlorine - piridinilmetoxi) anilino] - 3 - cyano - ethoxy - 6 - 7 - quinolinil} - 4 - (dimethylamino) - 2 - / with an anhydrous Organic Solvent, adding a solution of a Second Organic Solvent yagua,C is dissolved and filtered; maleate (e) - N - (4 - (3 - Chloro - 4 - (2 - piridinilmetoxi) anilino] - 3 - cyano - ethoxy - 6 - 7 - quinolinil} - 4 - (dimethylamino) - 2 - / with an anhydrous Organic Solvent containing Water,And filtered; and D redissolve maleate (e) - N - (4 - [3 - (4 - (2 - chlorine - piridinilmetoxi) anilino] - 3 - cyano - ethoxy - 6 - 7 - quinolinil} - 4 - (dimethylamino) - 2 - / with an anhydrous Organic Solvent containing water during a period of days, and filter.Claim 1: Isolation of a Crystalline form maleate monohydrate (e) - N - (4 - [3 - (4 - (2 - chlorine - piridinilmetoxi) anilino] - 3 - cyano - ethoxy - 6 - 7 - quinolinil} - 4 - (dimethylamino) - 2 - / characterized by diffraction Peaks x-ray in the Following Angles (+ - 2 Theta 0.20u00b0) in their pattern X-ray diffraction: 6.53, 8.43, 10.16, 12.19, 1247, 13.01, 15.17, 16.76, 17.95, 19.86, 21.11, 21.88, 23.22, 23.78, 25.69, 26.17, 27.06, 28.17, 28.26, 31.03 and 29.92. Claim 31: a Crystalline form isolated maleate (e) - N - (4 - [3 - (4 - (2 - chlorine - piridinilmetoxi) anilino] - 3 - cyano - ethoxy - 6 - 7 - quinolinil} - 4 - (dimethylamino) - 2 - / anhydrous, characterized by diffraction Peaks x-ray in the Following Angles (+ - 2 Theta 0.20u00b0) in their pattern of dif Reaction of x-ray: 6.16, 7.38, 8.75, 10.20, 12.24, 12.61, 14.65, 15.75, 17.33, 18.64, 19.99, 20.66, 21.32, 22.30, 23.18, 24.10, 24.69, 25.49, 26.09, 26.54, 27.52, 28.62, and 16.47.Claim 1: a Crystalline form isolated maleate (e) - N - (4 - [3 - (4 - (2 - chlorine - piridinilmetoxi) anilino] - 3 - cyano - ethoxy - 6 - 7 - quinolinil} - 4 - (dimethylamino) - 2 - / anhydrous, characterized by a starting temperature of 196u00b0C and the final temperature of 204u00b0C, as measured by the calorimetru00ed A differential Scanning.Claim: a Crystalline form of 34 isolated maleate monohydrate (e) - N - (4 - [3 - (4 - (2 - chlorine - piridinilmetoxi) anilino] - 3 - cyano - ethoxy - 6 - 7 - quinolinil} - 4 - (dimethylamino) - 2 - /, which has a Water content 2.5 to 2.7% in weight.Claim 35: a partially hydrated Crystalline form isolated maleate (e) - N - (4 - [3 - (4 - (2 - chlorine - piridinilmetoxi) anilino] - 3 - cyano - ethoxy - 6 - 7 - quinolinil} - 4 - (dimethylamino) - 2 - /, which has a Content of Water from 1.5% to 2.3% in weight.
机译:(e)-N-(4-[3-(4-(2-氯-piridinilmetoxi)anilino)]-3-氰基-乙氧基-6-7-喹啉}-4-(二甲氨基)-2的马来酸盐形式制备马来酸盐与晶体结晶相关化合物的形式的方法以及含有马来酸盐的药物组合物。马来酸盐可用于治疗癌症,尤其是那些受表皮生长因子受体家族激酶影响的盐。 (e)-N-(4-[3-(4-(2-氯-piridinilmetoxi)anilino]]-3-氰基-乙氧基-6-7-喹啉}-4-(二甲基氨基)-2的制备方法 /-作为马来酸盐,通过理解混合步骤来表征:(e)-N-(4-[3-(4-(2-氯-吡咯烷酮肟)苯胺基]]-3-氰基-乙氧基-6-7-喹啉} -4-(二甲氨基)-2-和/或马来酸在水醇溶液中的高温要求保护:特征在于14的化合物属于下式组成的组:式(1)的组。权利要求17的制备方法:马来酸酯一水合物(e)-N-(4-[3-(4-(2--氯-piridinilmetoxi)aniiino]]-3-氰基-乙氧基-6-7-喹啉)-4-(二甲基氨基)- 2-了解所选择的阶段,其特征在于:溶解马来酸酯(e)-N-(4-[3-(4-(2--氯-吡咯烷酮肟)苯胺基]]-3-氰基-乙氧基-6 -7-喹啉基}-4-(二甲基氨基)-2-/用无水有机溶剂,加水,并过滤; b。溶解马来酸酯(e)-N-(4-[3-(4-(2-氯-piridinilmetoxi)anilino]]-3-氰基-乙氧基-6-7-喹啉}-4-(二甲氨基)-2-用无水有机溶剂,添加第二有机溶剂yagua的溶液,将C溶解并过滤;马来酸酯(e)-N-(4-(3-氯-4-(2-piridinilmetoxi)anilino]]-3 -氰基-乙氧基-6-7-喹啉}-4-(二甲基氨基)-2- /用含水的无水有机溶剂过滤,然后D重新溶解马来酸酯(e)-N-(4-[3-( 4-(2-氯-piridinilmetoxi anilino]-3-氰基-乙氧基-6-7-喹啉}}-4-(二甲氨基)-2-//含无水有机溶剂,几天之内,然后过滤.Claim 1:分离结晶形式的马来酸酯一水合物(e)-N-(4-[3-(4-(2-氯-piridinilmetoxi)anilino]]-3-氰基-乙氧基-6-7-喹啉}-4 -(二甲氨基)-2- /的特征在于以下衍射峰X射线X射线衍射图上的角度(+-2 Theta 0.20 u00b0):6.53、8.43、10.16、12.19、1247、13.01、15.17、16.76、17.95、19.86、21.11、21.88、23.22、23.78、25.69、26.17, 27.06、28.17、28.26、31.03和29.92。权利要求31:结晶形式的分离的马来酸酯(e)-N-(4-[3-(4-(2-氯-piridinilmetoxi)anilino]]-3-氰基-乙氧基-6-7-喹啉}-4-(二甲基氨基)-2-//无水,其特征在于衍射以其x射线反应模式在以下角度(+-2 Theta 0.20 u00b0)达到峰值x射线:6.16、7.38、8.75、10.20、12.24、12.61 ,14.65、15.75、17.33、18.64、19.99、20.66、21.32、22.30、23.18、24.10、24.69、25.49、26.09、26.54、27.52、28.62和16.47。权利要求1:一种结晶形式分离的马来酸盐(e)-N- (4-[3-(4-(2-氯-piridinilmetoxi)anilino]-3-氰基-乙氧基-6-7-喹啉}-4-(二甲基氨基)-2-/无水,其特征在于起始温度为196℃,最终温度204℃,通过量热法A差示扫描测量。要求:34种分离的马来酸酯一水合物的结晶形式(e)-N-(4-[3-(4-(2 -氯-piridinilmetoxi)[anilino]-3-氰基-乙氧基-6-7 -喹啉}-4-(二甲氨基)-2- /,其水含量为2.5至2.7%(重量)。权利要求35:部分水合的结晶形式分离的马来酸酯(e)-N-(4-[3-( 4-(2-氯-piridinilmetoxi anilino]-3-氰基-乙氧基-6-7-喹啉}-4-(二甲基氨基)2-//,其水含量为重量的1.5%至2.3% 。

著录项

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号